


Summary

Name	Biglycan
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/μg as determined by LAL test.
Construction	Recombinant Human Biglycan is produced by our Mammalian expression system and the target gene encoding Glu20-Lys368 is expressed with a 6His tag at the C-terminus.
Accession #	P21810
Host	Human Cells
Species	Human
Predicted Molecular Mass	40.47 KDa
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

SDS-PAGE image



Background

Product Name: Recombinant Human BGN (C-6His)
Catalog #: PHH0153



Alternative Names

Biglycan; Bone/Cartilage Proteoglycan I; PG-S1; BGN; SLRR1A

Background

Biglycan is a 200-350 kD proteoglycan consisting of a 45 kD core protein and two chondroitin/dermatan sulfate glycosaminoglycan chains. Biglycan binds to TGF- β . It also binds to collagen type I in low ionic strength (less than 3 mM phosphate) buffer. At higher ionic strengths, Biglycan does not bind to collagen type I. It enhances the inhibition effect of TGF- β on osteoclast proliferation at a concentration of 4-20 mg/ml. It also prevents the attachment of CHO cells to fibronectin, with a 50% inhibition at 17-21 mg/ml.

Note

For Research Use Only , Not for Diagnostic Use.